Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab and Influenza Vaccine Interaction in Healthy Subjects
NCT03895385Phase 1Completed
- Sponsor
- UCB
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoints: Seroconversion response, Plasma concentration of bimekizumab (BKZ) and 1 more. Started Apr 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03895385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895385.